BANZEL Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6740669 | EISAI INC | Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic |
Nov, 2022
(10 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6740669 (Pediatric) | EISAI INC | Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic |
May, 2023
(4 months ago) | |
Banzel is owned by Eisai Inc.
Banzel contains Rufinamide.
Banzel has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Banzel are:
- US6740669*PED
- US6740669
Banzel was authorised for market use on 03 March, 2011.
Banzel is available in suspension;oral dosage forms.
The generics of Banzel are possible to be released after 14 May, 2023.
Drugs and Companies using RUFINAMIDE ingredient
Market Authorisation Date: 03 March, 2011
Treatment: NA
Dosage: SUSPENSION;ORAL
How can I launch a generic of BANZEL before it's drug patent expiration?
More Information on Dosage
BANZEL family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic